Fewer patients will be receiving the erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp

Fewer patients will be receiving the erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp.

Chronic kidney disease. ESAs are associated with an increase in death and cardiovascular events when used to boost hemoglobin above 12 g/dL. These drugs can increase thrombosis risk.

Kidney guidelines will recommend aiming for lower hemoglobin targets in the range of 11 to 12 g/dL.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote